A lung cancer drug developed by Akeso Inc. extended patients’ lives by about four months in a late-stage trial in China, ...
Experts have described the findings as a ‘promising step forward‘ for patients with advanced squamous non-small cell lung ...
SurvivorNet on MSN
A new type of immunotherapy drug showed striking results in hard-to-treat lung cancer, but more data is needed for US patients
A large clinical trial in China (HARMONi-6) found that a new immunotherapy drug, ivonescimab, may help patients with advanced ...
GlobalData on MSN
ASCO26: key readouts in lung cancer
At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various ...
A new study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that the targeted cancer ...
When Garen was diagnosed with lung cancer, biomarker testing helped focus his treatment options, inform his treatment ...
Results from a study on an investigational combination treatment for patients with advanced KRAS G12C+ non-small cell lung ...
A new study co-led by investigators at UCLA has found a drug can reduce the risk of re-acquiring lung cancer, it was announced Sunday. Researchers at UCLA’s Health Jonsson Comprehensive Cancer Center ...
Abenacianine, a fluorescent imaging agent, received FDA fast track status for enhancing tumor visualization during lung cancer surgery, showing safety and efficacy in phase 2 trials. Alecensa ...
Lung cancer is the most common and deadly form of cancer worldwide. It is increasingly understood to be a complex genetic disease with different mutations that vary according to factors such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results